Neoadjuvant and adjuvant chemohormonotherapy in patients with prostate cancer with high risk for progression


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Prostate cancer (PC) is an actual disease and a frequent oncological pathology in men. The detection rate of locally advanced and lymphogenic disseminated forms of prostate cancer in Russia remains high. Therapeutic tactics in PC patients is determined by the prevalence of the tumor process, the stage of the disease, and belonging to a risk group. In patients with a high and extremely high risk of disease progression, a multimodal approach can be considered. To date, there are many studies on neoadjuvant therapy, and there are also a number of works on adjuvant drug treatment. Neoadjuvant chemohormonotherapy at the first stage as part of a conditionally combined treatment demonstrates the advantage of this approach. Regarding the use of adjuvant chemotherapy, the data are contradictory. Further research is required to understand the appropriateness of this treatment approach. In the near future, probably, a multimodal approach to the treatment of patients of this cohort will be included in the standards of antitumor therapy.

Толық мәтін

Рұқсат жабық

Авторлар туралы

T. Ustinova

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

L. Bolotina

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Email: lbolotina@yandex.ru
MD, Head of the Department of Chemotherapy, Division of Drug Treatment of Tumors 3, 2nd Botkinsky passage, Moscow 125284, Russian Federation

N. Kharchenko

Peoples' Friendship University of Russia

Moscow, Russia

A. Paichadze

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

B. Alekseev

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

A. Kornietskaya

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

K. Isaeva

Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia

A. Kachmazov

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

A. Kaprin

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

A. Fedenko

P.A. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiology Center

Moscow, Russia

Әдебиет тізімі

  1. Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г В. Петровой. М. 2018
  2. Носов Д.А., Гладков О.А., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2017. С. 462-63
  3. Mohler J.L., Antonarakis E.S., Armstrong A.J., et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479-505. Doi: 10.6004/ jnccn.2019.0023.
  4. Mottet N, van den Bergh R.C.N., Briers E., et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. URL: https://uroweb. org/guideline/prostate-cancer.
  5. Clark P.E., Peereboom D.M., Dreicer R., et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57:281-85.
  6. Dreicer R, Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138-42.
  7. Friedman J, Dunn R.L., Wood D., et al. Neoadjuvant Docetaxel and Capecitabine in Patients With High Risk Prostate Cancer. Urology. 2008;179(3): 911-6.
  8. Garzotto M., Higano C.S., O'Brien C., et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer. 2010;116(7):1699-708.
  9. Hussain M., Smith D.C., El-Rayes B.F., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61:774-80. Doi: https://doi.org/10.1016/s0090- 4295(02)02519-0.
  10. Shepard D.R., Dreicer R., Garcia J., et al. Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy. Urology [Internet]. Am Urol Ass. 2009;181(4):1672-7. URL: http://dx.doi. org/10.1016/j.juro.2008.11.121.
  11. Womble P.R., Vanveldhuizen P.J., Nisbet A.A., et al. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. Urology [Internet]. Am Urol Ass Educat Res., Inc. 2011;186(3):882-87. URL: http://dx.doi. org/10.1016/j.juro.2011.04.087.
  12. Ross R.W., Galsky M.D., Febbo P.G., et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012; 118:4777-84. Doi: https://doi. org/10.1002/cncr.27416.
  13. Silberstein J.L., Poon S.A., Sjoberg D.D., et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. BJU. Int. 2015;116:50-6. Doi: https://doi.org/10.1111/ bju.12676.
  14. Febbo P.G., Richie J.P, George D.J., et al. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clin Canc Res. 2005;11(14). doi: 10.1158/1078-0432.CCR-05-0299.
  15. Chi K.N., Chin J.L., Winquist E., et al. Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer. Urology. 2008 August 2:565-70.
  16. Prayer-galetti T., Sacco E., Pagano F, et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU. Int. 2007;100(2):274-80.
  17. Sella A., Zisman A., Kovel S., et al. Neoadjuvant chemohormonaltherapyinpoor-prognosislocalized prostate cancer. Urology. 2008;71(2):323-27. doi: 10.1016/j.urology.2007.08.060.
  18. Pan J., Chi C., Qian H., et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Urol Oncol. 2019:1078-1439(19)30285-6. Doi: 10.1016/j. urolonc.2019.07.009.
  19. Thalgott М., Horn Т, Heck М., et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.J. Hematol. Oncol. 2014. https://doi. org/10.1186/1756-8722-7-20.
  20. Fujita N., Koie T, Ohyama C., et al. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. Int J Clin Oncol. 2017;22(6):1087-93.
  21. Tosco L., Laenen A., Briganti A., et al. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prost Canc Prost Dis. 2017;407-12.
  22. Nosov А, Reva S., Petrov S., et al. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study. The prostane 2016;76(15):1343-466.
  23. Нюшко К.М., Устинова Т.В., Пайчадзе А.А. и др. Неоадъювантная химиогормонотерапияи радикальная простатэктомия у больного лимфогенно-диссеминированным раком предстательной железы. Онкоурология. 2017;13(3):148-54.
  24. Narita S, Tsuchiya N., Kumazawa T., et al. Shortterm clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized p. World J Surg Oncol. 2012;10:2-7.
  25. Fizazi K., Faivre L., Lesaunier F., et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial. Lancet. Oncol. 2015;16(7):787-94. Doi: https://doi. org/10.1016/S1470-2045(15)00011-X.
  26. Nader R., Amm J., Aragon-Ching J. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-29. doi: 10.4103/aja. aja_40_17.
  27. Bergstrom C.P, Ruffell B., Ho C.M., et al. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates. J. Anticancer Drugs. 2017;28(1):120-26.
  28. Mellado B., Font A., Alcaraz A., et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101:1248-52. Doi: https://doi. org/10.1038/sj.bjc.6605320.
  29. Konety B.R., Eastham J.A., Reuter V.E., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. Urology. 2004;171:709-13. Doi: https://doi. org/10.1097/01.ju.0000108122.36893.5a.
  30. Thompson I.M., Tangen C., Basler J., Crawford E.D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. Urology 2002;168(3):1008-12.
  31. Sandler H.M., Hu C., Rosenthal S., et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol. 2015;33:LBA5002. Doi: https://doi.org/10.1200/JCO.18.02158.
  32. Hussain M., Tangen C.M., Thompson I.M. Jr., et al. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. NCT00004124. J Clin Oncol. 2018;20;36(15):1498-504. Doi: 10.1200/ JCO.2017.76.4126.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2019

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>